Search for content, post, videos

Bastian Dehmel appointed new CMO of OxThera


OxThera announces the appointment of Dr. Bastian Dehmel as their new Chief Medical Officer.

Dehmel joins OxThera after serving as Executive Medical Director and Global Development Leader for Amgen’s calcimimetic franchise. He has extensive experience in the life science sector, having led Medical Affairs and Clinical Development teams responsible for drugs in Diabetes and End Stage Renal Disease. Bastian brings extensive experience in working with global regulatory agencies and was responsible for FDA and EMA approval of etelcalcetide, and more recently for the orphan pediatric drug approval of cinacalcet by EMA.

“I am excited to join OxThera at this important juncture as we launch into the Oxabact Phase III pivotal study for patients with PH,” said Dr. Dehmel. “This is a devastating disease for patients and their families and I truly hope that we can make a real difference. I am excited to work with Matthew and the entire OxThera team to deliver on the promise of this new therapy.”


“It is my pleasure to welcome Bastian as CMO of OxThera,” said Matthew Gantz, CEO of OxThera. “His ​extensive experience in the renal space and successful track record of drug development in both the US and Europe will enable OxThera to rapidly progress the development of Oxabact for treating Primary Hyperoxaluria.”